Sugi Predict

Sugi Predict / Compounds / SCHEMBL30028870

SCHEMBL30028870

SCHEMBL30028870

CC(C)C[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1c[nH]cn1)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CS)C(=O)O

nearest known ligand 0.60

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
▸ GLP1R P43220 16/20 0.60
▸ SCTR P47872 1/20 0.60
▸ CALCR P30988 4/20 0.60
▸ GCGR P47871 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30874401 0.94 GLP1R (0.66) GLP1RSCTRCALCRGCGR
SCHEMBL30874397 0.94 GLP1R (0.66) GLP1RSCTRCALCRGCGR
SCHEMBL30108346 0.94 GLP1R (0.59) GLP1RSCTRCALCRGCGR
SCHEMBL30620994 0.93 GLP1R (0.68) GLP1RSCTRGCGR
SCHEMBL29692881 0.93 GLP1R (0.69) GLP1RSCTRGCGR
SCHEMBL30148474 0.93 GLP1R (0.67) GLP1RSCTRCALCRGCGR
SCHEMBL31291000 0.93 GLP1R (0.69) GLP1RSCTRGCGR
SCHEMBL30076320 0.93 GLP1R (0.69) GLP1RSCTRGCGR
SCHEMBL29692871 0.93 GLP1R (0.69) GLP1RSCTRGCGR
SCHEMBL30053976 0.93 GLP1R (0.69) GLP1RSCTRGCGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12383605-B2 Exenatide analog and use thereof ANYGEN CO., LTD. (KR) 2025-08-12 — — US disclosed
CN-115380043-A Exenatide analogue and application thereof 安医健有限公司 2022-11-22 — — CN disclosed
US-20220323548-A1 EXENATIDE ANALOG AND USE THEREOF ANYGEN CO., LTD., (KR) 2022-10-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12383605-B2 Exenatide analog and use thereof GLP1R, IAPP, GIPR GLP1R 1/4885SCTR 9/4885CALCR 695/4885
US-20220323548-A1 EXENATIDE ANALOG AND USE THEREOF GLP1R, IAPP, GIPR GLP1R 1/4885SCTR 9/4885CALCR 695/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback